Boston Scientific faces share pressure but holds strong in key medtech areas with growth potential.

Boston Scientific Corporation is experiencing share price weakness due to market share losses in electrophysiology and negative sector sentiment. Despite these challenges, the company remains a leader in pulsed field ablation (PFA) and has promising growth prospects with its Watchman device and neuromodulation technologies. Management has improved financial health by boosting margins, reducing short-term debt, and maintaining returns above capital costs. Currently trading at low valuations amid sector pessimism, the stock is rated Hold pending stabilization in electrophysiology market share and sector recovery.